Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53

American Journal of Pathology

Volumn 155, Issue 3, 1999, Pages 955-965

  Huang, Cheng Long ^a   Kohno, Nobuoki ^b   Inufusa, Haruhiko ^c   Kodama, Ken ^d   Taki, Toshihiko ^a   Miyake, Masayuki ^a  

^a Kitano Hospital   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MISSENSE MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032886796     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65195-4     Document Type: Article

References (54)

1. Cordon-Cardo C: Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am J Pathol 1995, 147:545-560
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253:49-52
3. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 1992, 70:523-526
4. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994, 54:4855-4878
5. Velculescu VE, El-Deiry WS: Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996, 42:858-868
6. Deb S, Jackson CT, Subler MA, Martin DW: Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol 1992, 66:6164-6170
7. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ: Gain of function mutations in p53. Nature Genet 1993, 4:42-46
8. Hann BC, Lane DP: The dominating effect of mutant p53. Nature Genet 1995, 9:221-222
9. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B: Definition of a consensus binding site for p53. Nature Genet 1992, 1:45-49
10. Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C: Wild-type p53 activates transcription in vitro. Nature 1992, 358:83-86
11. Cho Y, Gorina S, Jeffrey PD, Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994, 265:346-355
12. Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Miyake M: Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 1998, 16:2469-2477
13. Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, Weidauer H, Bosch FX: TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998, 16:1671-1679
14. Miyashita T, Harigai M, Hanada M, Reed JC: Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994, 54:3131-3135
15. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80:293-299
16. Sandri MI, Isaacs RJ, Ongkeko WM, Harris AL, Hickson ID, Broggini M, Vikhanskaya F: p53 regulates the minimal promoter of the human topoisomerase IIα gene. Nucleic Acids Res 1996, 24:4464-4470
17. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995, 377:646-649
18. Kieser A, Weich HA, Brandner G, Marme D, Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994, 9:963-969
19. Li ZH, Zhu YJ, Lit XT: Wild-type p53 gene increases MDR1 gene expression but decreases drug resistance in an MDR cell line KBV200. Cancer Lett 1997, 119:177-184
20. Linette GP, Li Y, Roth K, Korsmeyer SJ: Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci USA 1996, 93:9545-9552
21. Brady HJM, Gil-Gomez G, Kirberg J, Berns AJM: Baxα perturbs T cell development and affects cell cycle entry of T cells. EMBO J 1996, 15:6991-7001
22. Borner C: Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem 1996, 271:12695-12698
23. O'Reilly LA, Huang DCS, Strasser A: The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 1996, 15:6979-6990
24. Mazel S, Burtrum D, Petrie HT: Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med 1996, 183:2219-2226
25. Rolley N, Butcher S, Milner J: Specific DNA binding by different classes of human p53 mutants. Oncogene 1995, 11:763-770
26. Apolinario RM, Valk P, Jong JS, Deville W, Ark-Otte J, Dingemans AC, Mourik JC, Postmus PE, Pinedo HM, Giaccone G: Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997, 15:2456-2466
27. Mountain CF: Revisions in the international system for staging lung cancer. Chest 1997, 111:1710-1717
28. McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT, Seigler HF, McCarty KS Sr: Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986, 46:4244s-4248s
29. Brambilla E, Negoescu A, Gazzeri S, Lantuejoul S, Moro D, Brambilla C, Coll JL: Apoptosis-related factors p53, bcl2 and bax in neuroendocrine lung tumors. Am J Pathol 1996, 149:1941-1952
30. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481
31. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170
32. Cox DR: Regression modes and life-tables. J R Stat Soc B 1972, 34:187-220
33. Rubin L, Philpott KL, Brooks SF: The cell cycle and cell death. Curr Biol 1993, 3:391-394
34. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC: Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992, 69:119-128
35. Haas-Kogan DA, Kogan SC, Levi D, Dazin P, T'Ang A, Fung YK, Israel MA: Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 1995, 14:461-472
36. Vairo G, Innes KM, Adams JM: Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 1996, 13:1511-1519
37. Strasser A, Huang DCS, Vaux DL: The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim Biophys Acta 1997, 1333:F151-F178
38. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993, 74:609-619
39. Yin XM, Oltvai ZN, Korsmeyer SJ: BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994, 369:321-323
40. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY: bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993, 329:690-694
41. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G: Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995, 71:1003-1007
42. Kitagawa Y, Wong F, Lo P, Elliott M, Verburgt LM, Hogg JC, Daya M: Overexpression of bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers. Am J Respir Cell Mol Biol 1996, 15:45-54
43. Ishida H, Irie K, Itoh T, Furukawa T, Tokunaga O: The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer 1997, 80:1034-1045
44. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK: bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. J Clin Oncol 1997, 15:1916-1922
45. Marx D, Binder C, Meden H, Lenthe T, Ziemek T, Hiddemann T, Kuhn W, Schauer A: Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res 1997, 17:2233-2240
46. Tsujimoto Y, Croce CM: Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986, 83:5214-5218
47. Minna JD: Neoplasms of the lung. Principles of Internal Medicine. Edited by Isselbacher KJ. New York, McGraw-Hill, 1991, pp 1102-1110
48. Pavletich NP, Pabo CO: Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A. Science 1991, 252:809-817
49. Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, Sigler PB: Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 1991, 352:497-505
50. Ellenberger TE, Brandl CJ, Struhl K, Harrison SC: The GCN4 basic region leucine zipper binds DNA as a dimer of uninterrupted alpha helices: crystal structure of the protein-DNA complex. Cell 1992, 71:1223-1237
51. Iwamoto KS, Mizuno T, Ito T, Tsuyama N, Kyoizumi S, Seyama T: Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. Cancer Res 1996, 56:3862-3865
52. Park DJ, Chumakov AM, Miller CW, Pham EY, Koeffler HP: p53 transactivation through various p53-responsive elements. Mol Carcinogen 1996, 16:101-108
53. Crook T, Parker GA, Rozycka M, Crossland S, Allday MJ: A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear:cytoplasmic shuttling defect. Oncogene 1998, 16:1429-1441
54. Kawamura M, Yamashita T, Segawa K, Kaneuchi M, Shindoh M, Fujinaga K: The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity. Oncogene 1996, 12:2361-2367